Zofran Birth Defect Lawsuit Alleges Drug Caused Son’s Hypoplastic Right Heart Syndrome

October 29, 2015 – – ZofranLegal.com reports on a lawsuit filed in July by a single mother from Illinois who claims that her use of anti-nausea medication Zofran while pregnant caused her son to be born with significant heart defects. The claim, filed under case number 3:15-cv-00769, states that she was prescribed Zofran for nausea during her first trimester of pregnancy, and subsequently delivered a baby with hypoplastic right heart syndrome.

The mother is joined by many others who were prescribed Zofran in an “off-label” fashion to combat morning sickness commonly experienced with pregnancy. This is termed an “off-label” prescription, because the drug was never approved for this use. It was also never tested on expectant mothers for safety.

Zofran was approved by the U.S. Food and Drug Administration in 1991 to treat patients suffering from significant nausea and vomiting episodes after undergoing chemotherapy, radiation, and anesthesia procedures. After this approval, however, Zofran manufacturer GlaxoSmithKline marketed the drug to pregnant women as well as obstetrics and gynecological offices. Across the United States, millions of women are prescribed the drug to use while pregnant.

In this particular complaint, the son was born with his right heart significantly underdeveloped. The condition is considered a severe one, as it also indicates that the child’s pulmonary valve, which assists blood flow in reaching the lungs, is fully absent. The condition requires immediate medical intervention to save the child’s life. There is no definitive cure, but surgeons are able to perform certain procedures to help improve blood flow through open heart surgery. In some cases, a full heart transplant may be the only option for survival.

This mother states that her child had to undergo a transplant procedure very shortly after he was born, to replace his significantly defective heart with a donor heart. Her lawsuit is joined by a majority of others which also allege that heart defects are the number one birth defect children suffer after being exposed to Zofran while in utero. The women also state that they were given Zofran during their first trimester of pregnancy. This happens to be the time when a fetus’ heart goes through most of its formation and development.

The lawsuits filed against this drug and manufacturer GlaxoSmithKline are expected to continue to appear across the nation. The Zofran attorneys at Monheit Law are currently working to help anyone who has given birth to a child with defects after using the drug explore their legal rights. They provide free consultations, so that victims are potentially able to seek compensation.

For additional information concerning this topic, or to ask questions, contact Attorney Michael Monheit directly by calling 877-620-8411 today.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60004957